報價延遲最少15分鐘:2025/06/01 02:13 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.95 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.98/-0.59
|
|
企業價值
16.08M
|
| 資產負債 |
|
每股賬面淨值
2.65
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
501.00K
|
|
每股收益
0.02
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/01 02:13 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105. |